INFI - Bragar Eagel & Squire P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Infinity HUB and Shift4 and Encourages Investors to Contact the Firm | Benzinga
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Hub Cyber Security Ltd. (f/k/a Hub Cyber Security (Israel) Ltd.) (NASDAQ:HUBC, HUBCZ, HUBCW)), and Shift4 Payments, Inc. (NYSE:FOUR). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)
Class Period: January 5, 2022 - July 24, 2023
Lead Plaintiff Deadline: October 16, 2023
For over a year, Defendants pushed the false narrative that Infinity's flagship product, eganelisib, was proceeding apace in its clinical studies as a treatment for breast cancer. Specifically, Infinity touted two clinical studies: (1) MARIO-4, a randomized, double-blind Phase 3 study; and (2) MARIO-P, a platform study to evaluate additional combinations and indications where eganelisib might increase the effectiveness of available therapies.
Results were initially so promising that partners were being sought (and prospective partners were interested) to bring eganelisib to the next stage. Then, overnight, the promise vanished. A merger was announced with another pharmaceutical company, and breast cancer treatment wasn't mentioned. It was as if neither MARIO-4 nor MARIO-P existed. The new entity would now focus on head and neck cancer. The stock market reaction was predictable. Investors fled in droves on ...